Table of Contents

3.0.28 Release Notes	2	
Prepare for 21st Century Cures Act automatic release of clinical notes	2	
Releasing signed clinical notes by template type		2
Comply with DEA regulations when ordering controlled substances	4	
Identify regimen evidence levels more quickly	5	
Save a click with clinical notes copy forward feature	5	
Easily filter docked or un-docked clinical notes	7	
Add associated problems to orders more efficiently	7	
Identify patients faster with attending provider appended to search results	8	
Support payer inquiries with the enhanced Administered Medic- ations Report	8	
Support for COVID-19 booster and brand mixing in Charge Capture	9	
First Dose		9
Second Dose	1	0
Third Dose	1	0
Booster Dose	1	0
Texas immunization consent tracking	0	
Additional Enhancements 1	3	
Fixed Defects 1	3	

3.0.28 Release Notes Jan 2022

iKnowMed Generation 2 version 3.0.28 introduces important updates around Clear Value PlusSM Compliant Regimens, clinical notes enhancements, additional vaccine codes for boosters and brand mixing, and various fixed defects, and various other improvements.

Prepare for 21st Century Cures Act automatic release of clinical notes

To further meet the requirements of the 21st Century Cures Act, iKnowMedSM Generation 2 version 3.0.28 includes enhancements to support the future immediate release of signed clinical notes to patient portals.

NOTE: Although these features are functional post-release, no notes will be automatically sent to patient portals at this time.

The goal is to help practices begin designating types of signed notes that should be withheld for patients pursuant to state law, or if there is a risk of substantial harm.

By acting now, practices can prepare for when the automatic release of signed notes goes live so that there is minimal interruption to their workflows. As a reminder, physicians will always have the choice to withhold signed clinical notes once the automatic release is live.

Releasing signed clinical notes by template type

Practices can designate which types of signed clinical notes should or should not be automatically released to patient portals in two ways:

1. Super Users can go to Manage > Clinical Note Templates and manually edit each clinical note template by checking the new Signed Note Available in Portal option (see callout 1).



 If this option is too inefficient, practice users with full clinical note templates permission can use the new Release to Patient Portal feature on the Manage > Clinical Note Templates landing page (see callout 2).

These users can select one or more templates from the list and choose to turn **On** or **Off** the automatic release of these signed notes to the patient portal (see callout 3). Due to pagination, bulk selection will only apply to the templates listed on the shown page.

The page will also display whether this feature is **On** or **Off** for each template under the new **Release to Patient** column (see callout 4). This gives users a broad view of which templates were updated.

Man	age Clinical Note Tem	plates							
ADD	TEMPLATE EDIT COPY	REMOVE PRINT	VIEW Release to	Patient Portal					
Displa	ay Templates Owned By User	Search User Nam	10	🖌 Show All U	Jsers' Templates				
Displa	ay Templates Of Category:	All	~	follow					
3	y Release to Patient Portal:	All	~						
	Name		Category		4. Release to Patient	Owner	Private Access	Suppress Display	Last Modified Date
	#Follow UP				01	ZZThibideau, Rachel, Product Portfolio Mgr	False	False	01/25/2022
	*Follow Up					ZZGarza, Alicia, Product Owner	False	False	01/03/2022
	*Follow UP					ZZThibideau, Rachel, Product Portfolio Mgr	False	False	10/22/2021
	2- Follow-up (mn)					ZZNubie, MadelineObsolete, RN	False	False	04/25/2013
	Alec Follow Up					Soreff, Alec, Custom Report	False	False	03/31/2020
	AOA Follow Up Example					ZZHarruff, Marla, Exec Implementation Spc	True	True	11/15/2021
	Athens Follow up					ZZGray, Rob	False	False	01/06/2016
	Athens follow up					Alpha, Doctor, Sr.	False	False	01/06/2016
	CHART PREP Follow up N	lote				ZZRodriguez, Luis, Tech Prod Support	False	False	11/02/2021
	CSW Counseling Follow-U	lp				ZzMills, Lydia, Sr. Mngr. Supportive Care	False	False	05/19/2020
	CSW Counseling Follow-U	lp				ZZWalton, Taura, Account Manager	False	False	05/28/2020
	Demo Follow up					ZZGarza, Alicia, Product Owner	False	False	12/09/2020
	Derick Follow Up					ZZVenters, Derick, Sr. Product Portfolio Mgr	False	False	03/31/2020
	Derick Follow Up Test					ZZVenters, Derick, Sr. Product Portfolio Mgr	False	False	03/12/2020
	Diana Follow Up					Hale, Diana	False	False	03/31/2020
	Dr. Sarma Example Follow	r up Note				ZZWalton, Taura, Account Manager	False	False	10/20/2017
	DrC Followup note					ZZPittman, Crystal, Iknowmed Trainer	False	False	06/15/2021

📧 🕢 1-17 of 248 🕟 🕅

IMPORTANT: Any newly created clinical note templates will automatically be set to release those signed notes to patient portals. Practices must actively remove this setting if they wish to withhold those signed notes.

Lastly, a future release will give users the ability to withhold individual signed clinical notes to account for exceptions where the note must be reviewed by a physician before it can be sent to the portal.

Comply with DEA regulations when ordering controlled substances

Two-factor authentication for electronically prescribing controlled substances adds a layer of security when identifying a provider's identity and is a federal requirement set by the U.S. Drug Enforcement Agency (DEA). Meeting this DEA requirement is also required for EHR certification.

To meet this requirement, when electronically prescribing controlled substances in iKnowMed Generation 2, a new required field will be introduced. Providers will need to enter their signing PIN or password in this field.

At the time of saving an electronic prescription order for one or more controlled substances, providers will see the Digital Signature pop up and must enter their Signing PIN or Password (see callout 1) followed by the designated second factor - Push Notification or Soft or Hard Token.

Digital Signature	
This medication(s) requires t Complete the fields below ar medication. By completing the two-factor the prescription(s) and autho	wo-factor authentication to be prescribed electronically. In press Submit or Send Push Notification to prescribe this authentication protocol at this time, you are legally signing rizing the transmission of the above information to the
pharmacy for dispensing. Th by the practitioner whose na	e two-factor authentication protocol may only be completed me and DEA registration protocol may above.
Enter Signing PI	N or Password
Option 1 - Push	Notification
A push notification will be ser upon receipt.	nt to your personal device. Please respond immediately
	SEND PUSH NOTIFICATION
Option 2 - Passc	ode
	Hard Token 💿 Soft Token
One time pass	CANCEL

Identify regimen evidence levels more quickly

We're making it easier to get the information you need at a glance with visual enhancements in Clear Value PlusSM Treatment Options.

Quickly identify NCCN category of evidence levels for regimens in Clear Value Plus. For NCCN regimens, the category of evidence will now display in the NCCN w/ Evidence column (see callout 1).

For practices using P&T Preferred pathways, we've changed the color of icons for regimens in the P&T Preferred pathway column making it easier to recognize (see callout 2).

Clear Value Plus - Pa	Sear Value Plus - Pathway Decision Support												
Add Photo	InsuranceAuth1 A Post (567/F) Sol: boot boot boot boot boot boot boot boo												
Regimen Type			Medical Info	Value Pathways Evidence	8			Filter Ch	emotherapie	s by:			CLEAR
 Regimen Type: 	Chemotherapy	EDIT									Febrile		
Diagnosis	0		SHOW Clinica						2	9	Neutropenic Risk	Risk	
Primary Diagnosis: Staging Information	of lung (disorder)		HIDE Treatm					Value Pathways	P&T	NCCN w/	Febrile Neutropenic	Emetogenic Risk	
✓ Stage:	IVA	EDIT									Risk		
 Line of Therapy: 	Maintenance	EDIT	Atezolizumab					~	~	1	low	low	HIDE OPTIONS
			Atezolizumab Q210	0 6				~	~	1	low (<10%)	minimal (<10%)	SELECT
Search All Regimens		-	Atezolizumab Q140	0 6				~	~	1	low (<10%)	minimal (<10%)	SELECT
Used by decision supp	ort		Atezolizumab Q280	o &				~	~	1	low (<10%)	minimal (<10%)	SELECT
			Durvalumab					~		1	low	low	SHOW OPTIONS
SHOW Other Regimens (43) Value P&T NCCH w/ Petrone Pathways Preformed Evidence Residence Reside			Febrile Neutropenic Risk	Emetogenic Risk	Action								
	SAVE CANCEL												

Save a click with clinical notes copy forward feature

The new Copy Forward Recipients setting for clinical note templates saves providers a step by automatically adding recipients from the most recently sent note to the current note.

This feature is template based. To activate this feature:

- 1. Go to Manage > Clinical Note Templates.
- 2. Locate and select the preferred notes template.
- 3. Click the EDIT button.
- 4. Ensure the new **Copy Forward Recipients** setting is turned on (see callout 1).
- 5. SAVE your changes.

In a future release, users will be able to do bulk updates for Copy Forward Recipients.

Template Detail	* required
Template Category: Template Name: * (The name that will appear as the default document name) Template Name: Template Own Uncategorized #Follow UP ZZThibideau, F OTHER ACTIONS Template Name: * (The name that will appear as the default document name) Template Name: * (The name that will appear as the default document name)	er: Rachel, Product Portfolio Mgr
Font · Size · B I ∐ A, A* I ⊞ = = = I □ □ ⊕ ⊕ ♥ × >	Macros Sections Templates Search Macro Macros
#PracticeLetterhead Patient Name: #PatientDateOffinh DOB: #PatientDateOffinh MRN: #PatientDateOffinh RAttendingPhysician: AttendingPhysician Date of Service: 1022/2021 CHIEF COMPLAINT	#AdvanceCarePlanning #AdvanceCarePlanning #AdverseEvents #Allergies #Allergies #Allergies #Anc #Appointment.ocation #AttendingPhysician *
TUMOR STAGING #Problems[InitialCap Yes_LISTType:Bulleted PrincipalOnly Yes) TREATMENT HISTORY PAST MEDICAL HISTORY Usual childhood linesses. macular deceneration of left eve. bursitis. and history of	
Suppress Display Mark as Private Needs Review Signed Note Available in Portal Copy Forward Recipients	

The first time a note is created post-release, users must still add their intended recipients. After the initial note is signed and sent, the copy forward feature activates, and those same recipients will be automatically added to subsequent notes in the Send to line (see callout 2).

> 🧿 Aspen Tree (67 / F) - Hospice 🔇 🚥 🗢 🕘 🐹 DOB: 10/23/1954 MRN: app123 Attending: Multiple Dx: Bro	ast cancer Dx: Colon cancer 🛕 Ht/Wt/BSA: 65 in / 1500 lb / 5.59 m2 Allergies: Sulfa (Sulfonamide Antibiotics)
🔆 Chart Summary Clinical Profile Flowsheet 🥒 Orders Results Documents Demogra	phics Nursing Care Scheduler Admix Charge Capture - DECISION TOOLS
Document Name: * #Follow UP Date Of Service: 01/25/2022	Last Note Recognized Concepts Dictation List Billing Templates Macros Sections
DICTATION OTHER ACTIONS Note Reviewer:	Note Filters Show All
Send to: Dave J. Smith, MD (Referring) X Dr. Jenny Jones (Referring) X	Last Note *Follow Up (garza, alicia / 01/03/2022) V
	Document
Font \cdot Size \cdot B $I \ \underline{U}$ A ₂ A ² \underline{T}_x \underline{II}_x II	San Francisco Medical Oncology
II =	San Hancisco medical oncology
Surrow Source 194 S. Curroado Dr. 5 Sure A Hermant Sindhu, MD Surrow Sura, AZ. 26433 Hermantology - Oncology Www.undWeaturearearea Hermantology - Oncology Phone (197) 25:36420 Andrew Tackmann, MD Phone (197) 25:36420 Andrew Tackmann, MD	123 MISSION STREET SAN FRANCISCO, CA 94105 TELEPHONE: 415.867.5309 • FAIC 628.123.4567
F0X (520) 220-5028	Patient MN: app123 Patient MN: pp123
Patient Name: Aspen Tree DOB: 10/23/1954 MRN: asp123 Attending Physician : Doctor Pink (Medical Oncotoov), Doctor Alpha (Medical Oncotoov), Doctor Purole (Medical Oncotoov)	Patenti LOC: 1023/1504 Date of Service: 01/03/2022
Date of Service: 10/22/2021	Chief Complaint:
CHIEF COMPLAINT	 Breast cancer (Stage Date: Unknown, Stage IA (aft breast lower-inner quadrant, T2, N2a, cM0(+), G1, ER Status: Positive, PR Status: Positive, HerSZnieus Status: Positiveneroparatal:) Histopathologic Type: DCIS: Menopausa Status: Positiveneroparatal:) Colon cancer (Stage Date: C2022/03). Stage IA (Primary, Desconding colon, T3, N1, cM1a)-Pathological Date of Dx2022/01 Metastatic Sites: Done, Metastatic Sites: Liver; KRAS Mutation: Wid-type: NRAS Mutation: Wid- hom statistic Sites: Done, Metastatic Sites: Liver; KRAS Mutation: Wid-type: NRAS Mutation: Wid- hom statistic Sites: Done, Metastatic Sites: Liver; KRAS Mutation: Wid-type: NRAS Mutation: Wid- hom statistic Sites: Done, Metastatic Sites: Done, Metastatic Sites: Liver; KRAS Mutation: Wid-type: NRAS Mutation: Wid- hom statistic Sites: Done, Metastatic Sites: Done, Metastatic Sites: Liver; KRAS Mutation: Wid-type: NRAS Mutation: Wid- hom statistic Sites: Sites: Done, Metastatic Sites: Done, Metastatic Sites: Sit

NOTE: If a user sends a note to additional providers after the initial send, the next note created will only include the recipients of the most recent send. For example, if two providers are sent a note upon signing and then an additional provider is sent the note by fax or direct exchange from the Documents tab, only the additional provider will be visible in the Send to line in the next note. This is because the code only looks for the most recently sent set of recipients. On the subsequent note the 2 original providers will need to be added back into the recipients list.

Easily filter docked or un-docked clinical notes

When creating a clinical note, users can now view their document filters whether or not the note is docked.

Users will see a new **Note Filters** drop-down that allows them to use their personalized document tabs to filter the **Last Note** drop-down by document type (see callout 1).

Choosing a document type will filter the **Last Note** drop-down to only display notes that match the chosen category, making it easier for users to locate specific notes.

The drop-down also mimics the personalized document tabs of docked notes, meaning up to 15 document types will be present when filtering un-docked notes.



Add associated problems to orders more efficiently

The associated problems field in the order editor for medications, labs, imaging, and other services has been enlarged so that less scrolling is needed to view and select the appropriate options (see callout 1). The field is now taller and wider.

ontada®

iKnowMed Generation 2 — 3.0.28 Release Notes

Prior to Next Visit CBC Prior to Ne	xt Visit from 01/25/2022	(Status: Draft)			• required				
Today Tomorow Per Instruction Or Return AGAOn ASAP STAT Next Available Next Visit Next Visit with MD Next Vi	1 Day 2 Days 3 Days 4 Days 5 Days 6 Days 7 Days 8 Days 9 Days 10 Days 12 Days 14 Days 2 Carse x Starting In Week(s)	Within 1 Week U Weeks Weeks Weeks Weeks Weeks Weeks Weeks Weeks U W Weeks U Weeks U W Weeks U Weeks U W W Weeks U W W Weeks U W W W W W W W W W W W W W W W W W W W	Vithin 1 Month Months M	Calendar Dates c <th colspa="4" colspa<="" colspan="4" td=""><td></td></th>	<td></td>				
Asociated problems Acquired hypogammaglobulinemia Breast cancer (105.03.12 Maignail Breast cancer, (105.03.12 Maignail Breast cancer, (105.03 Maignain the Colon cancer (105.05	Create a n nt neoplasm of lower-inner qu- seoplasm of descending color ype 2 diabetes mellitus with c ancer (050.912 Malignant ne 11.1 0.1 Voniting, unspecified) er) *	order Instru adrant of Locatic Uter oplasm Bill: Insu	DD mm Location * Perfor gjon-Boulder * 0 Ur rance Research O Do Not	That Comments	arch Locations				

Identify patients faster with attending provider appended to search results

The name of all attending providers associated with a patient will display in alphabetical order when users search for a patient. We applied this update to all areas in iKnowMed Generation 2 where users can search for a patient (see callout 1 for an example).

This enhancement makes it easier for users to identify the correct patient if their date of birth or MRN is not readily available.

iKnowMed [™] Generati	ion 2	Q	smith, john		🖂 🖾	Alpha Central Region-Boy	i Oncology Ider Clinic - 01/25	5/2022
andrew's Dashboard	Aspen Tree (67 / F) - Hospice	ĸ	Smith, John Smith, John	(DOB:07/07/1940 / M (DOB:04/07/1949 / M	/ ID: 6897084765); (Alp / ID: G12345678); (Fillr	ha, Doctor: Attending) nore, Seth: Attending)		
> 🧑 Aspen Tree (67 /	F) - Hospice 🌖 осм 🎓 🚺	DOB: 10/23/19	Smith, John 54 MRN: app.	(DOB:07/07/1940 / M IZ3 Attending: Mul	/ ID: 42642); (Baltz, An tiple Dx: Breast cancer	nyMD: Attending)	Ht/Wt/BSA: 65 i	n / 1500 lb ,
📩 Chart Summary	Clinical Profile Flowsheet	t 🥒 Orders	Results	Documents	Demographics	Nursing Care	Scheduler	Admix
New Orders (0)	dications (0) Regimens (0) 🚽 On	der Review	Order Histor	ry 🥒 Drafts				
New Orders				PRECISION MEDIC	CINE 🥵 Associate	ed Problem No problem	n selected Order	r Search:

Support payer inquiries with the enhanced Administered Medications Report

The Administered Medications Report is frequently used to assist practices with supporting inquiries from payers on specific claims. The report has been enhanced to fill gaps identified by payers, making the report a more valuable tool for addressing payer inquiries.

The following items have been added:

- Credentials: the credential of users (i.e., RN, MD) are now included wherever a user's name is referenced.
- Incident to: the "incident to" provider documented on the MAR now prints on the report.
- Cosigning of treatment day approval: audit information for each co-signed treatment day approval for each applicable order has been added. The line reads, "Treatment day order signed by" followed by the doctor's name, credentials, and date/time stamp.
- Reword "Signed by": the previous version of the report included a line for each order that read "Signed by (doctor's name)." This line referred to when the original regimen order (not the treatment day approval) was signed. The line now reads "Original order signed by: (doctor's name)."

Support for COVID-19 booster and brand mixing in Charge Capture

iKnowMed Generation 2 now supports several new sets of COVID-19 vaccine administration codes, including:

- Booster dose administration billing for the Pfizer, Pfizer Tris, Johnson & Johnson, and Moderna COVID-19 vaccines.
- First and Second dose administration billing for the Pfizer Pediatric COVID-19 vaccine.
- Mixing of brands for Booster doses.

The workflow for documenting vaccines has not changed. On-site vaccines are tracked in the MAR, and off-site administrations are tracked in Clinical Profile > Health Maintenance.

The system infers which shot the patient is receiving based on the brand, the number of vaccines given in the **MAR**, and any **Health Maintenance** records for a COVID-19 vaccine marked as given **Elsewhere**.

The logic for determining the first dose, second dose, third dose and booster dose is listed below.

First Dose

Patient is receiving the COVID-19 vaccine for the first time in their medical record, and there is no entry in their **Health Maintenance** record to show that the patient has received a shot **Elsewhere**.

Second Dose

Patient is receiving the COVID-19 vaccine medication for the second time in the MAR.

or

Patient is receiving the COVID-19 vaccine medication in the **MAR**, and there is an entry in their **Health Maintenance** record with comment **Elsewhere** to show that the patient has received their first shot off-site.

Third Dose

This does is also known as an **Additional Dose** and only applies to doses that occur within six months of the date of the second dose of Pfizer or Moderna brand vaccines.

The patient is receiving the COVID-19 vaccine medication for the third time in their medical record in the **MAR**.

or

There are two entries in their **Health Maintenance** record with comment **Elsewhere** to show that the patient has previously received two doses off-site and is now receiving their first dose administered in the **MAR**.

or

There is one entry in their **Health Maintenance** record with comment **Elsewhere** to show that the patient has received one dose off-site, and they are receiving a second dose in the **MAR**.

Booster Dose

Patient is receiving the COVID-19 vaccine medication six months or more after the first dose of Johnson & Johnson or the second or third dose of Pfizer.

The Moderna booster administration code is linked to the dose of the medication being used. When the dose is .25mL the system will generate the booster code.

Texas immunization consent tracking

The state of Texas ImmTrac system added a requirement to their immunization registry called Affirmation Consent. To support this requirement, we added a new setting in **Demographics** to document immunization consent given by the patient.

This consent is in addition to the existing consent to participate in the Disease and Treatment Registry.

The consent documentation in demographics has two parts:

- 1. A checkbox to confirm the patient has consented, and
- 2. A radio button to select the demographic to which the patient belongs

When using the consent checkbox, the radio button selection is required prior to saving.

Because this requirement only applies to the state of Texas, there is a new **Practice Preference** to control whether the setting is included in the **Demographics** for your practice.

To use the new ImmTrac Consent feature:

- 1. Go to Admin > Practice Preferences and scroll down to the Other Features section.
- 2. Select the checkbox labeled **Show Texas ImmTrac Consent in Demographics** (see callout 1).
- 3. Click the **Save** button. You must log out and back in for the setting to apply to your practice.
- 4. The **Demographics** settings will now appear for all patient charts within your practice.
- 5. Open a patient and navigate to the **Demographics** tab.
- 6. Scroll down to the Patient Preferences section.
- In the Consents sub-section, there is now a checkbox labeled Texas ImmTrac Consent, which should be used to track the patient's consent (see callout 2)
- 8. Once the checkbox is selected, the radio buttons will be enabled. You must select a radio option to save the consent (see callout 3).
- 9. The selections will then be transmitted to ImmTrac.

iKnowMed Generation 2 — 3.0.28 Release Notes



Other Features		
Advance Care Planning	Enabled 🗸	
Brand Drug HCPCS Lookup	Enabled Y	
nnovent Disease Management	Enabled	
Dicology Care Model		
	Enabled	
Serious lliness Care	Enabled 🗸	
CDS Tools	Enabled 💙	
Precision Medicine	Enabled 🗸	
Add Lot# to Admix Label	Enabled V	
/arian Aria Report URL	http://174.128.24.106:80/reports.aspx?	
Custom Links Menu URL #1	https://virginia.pmpaware.net/login	
Custom Links Menu Display Name #1	VA PDMP	
Custom Links Menu URL #2	https://ctms.usoncology.com	
Custom Links Menu Display Name #2	CTMS	
Custom Links Menu URL #3		
Custom Links Menu Display Name #3	nuli	
Enable Zyno Pump Web Service	Not Epobled	
Enable Zvno Pump Updating Non-Test Patients	Not Enabled	
ASCO Cancerl inO	Not Enabled	
	Enabled	
Jse Advanced Editor for messages		
Show Texas ImmTrac Consent in Demographics		
Jnified Sign Queue	Enabled	
Patient Preferences		
reatment Location	Hospital	In House Testing Allowed
Central Region-Boulder Clinic V		Please Select ✔
aboratory	Pharmacy	Preferred Facility
Consents		
Disease and Treatment Registry		
Texas ImmTrac Consent 2	Patient Reminders	
Disaster (all ages)	Opt Out of Reminders	
Patient < 18 years old		
Fauent >= 18 years old	3rd Party application access Not Se	elected V
atient Portal Not Selected Y		

Additional Enhancements

Location (A-Z)	Details
Admin > Practice Preferences	All practices have been successfully migrated to the new Esker faxing service. As a result, we removed the Use Esker SaaS to Fax option from Other Features.
Admin > Users	A valid email address will now be required for all new users or existing users when user details are edited.
Results tab	White space has been removed, allowing the display of a few more lines of a result in the right pane.

Fixed Defects

Location (A-Z)	Details
Orders tab	Search results for medication orders will no longer present users with custom medications created by other practices. Users will only see results for medications their practice subscribes to for orderables.
Patient Chart > Flowsheet	Users can no longer mix clinical approval options in a regimen treatment day. For example, a regimen treatment day already approved to be administered offsite must have any added orders approved for offsite administration as well. When adding orders, all non-matching clinical approval options will be disabled to prevent the corruption to the regimen, MAR, and Flowsheet that occurs when mixing clinical approvals on the same treatment day in the same regimen.
Worklist Queues >	Renewal requests will no longer fail to match a patient

iKnowMed Generation 2 — 3.0.28 Release Notes



Location (A-Z)	Details
eRx Message	due to chart merges. This fix only applies to renewal requests made after the release of version 3.0.27 and will increase the frequency of successful matches for ongoing renewal requests.
Charge Capture Report	The correct administration code will now be produced for the following immunizations based on the settings of the medication in Manage > Medications:
	 When the Category is set to Vaccine > Influenza, the system will capture the code G0008.
	 When the Category is set to Vaccine > Hepatitis B, the system will capture the code G0010.
	• When the Category is set to Pneumococcal, the system will capture the code G0009.
	• When the Category is set to Other, the first administration will capture the code 90471. If additional Other vaccines are administered, each will capture the code 90472.
Clinical Notes > Macros	Special characters causing elastic search errors resulting in failures of the #CopyPreviousSection macro will now be automatically corrected if present in the section name or section itself.